Where is your ophthalmology specialty medication workflow slowing you down?

In the latest episode of The Retina TL;DR with Dr. Weng—Part 2 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two more of her former residents for candid advice on transitioning into fellowship, balancing research and family, and what excites them most about the future of retina.

In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.

An association has been identified between primary open-angle glaucoma and erectile dysfunction.

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

Himani Goyal, MD, reviews a patient case and discusses what a multispecialty group is seeing in practice.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.